Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03424590
Other study ID # PROTOCOL-0987
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 29, 2018
Est. completion date September 19, 2018

Study information

Verified date July 2018
Source SPD Development Company Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clearblue Connected Ovulation Test System (COTS) has been designed for home use by women who are either planning or trying for a pregnancy. This study will determine the difference in pregnancy rate of female volunteers seeking to get pregnant who use COTS in comparison to those not using an ovulation product to assist with conception.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date September 19, 2018
Est. primary completion date September 19, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Actively trying to conceive

- At least 2 regular consecutive cycles since last pregnancy/ miscarriage/ or since stopping breastfeeding

- Willing to use their own smartphone for the duration of this study and to download and install the study app

- Willing to disclose their pregnancy status and provide urine samples to test markers related to pregnancy and fertility

- Have internet access on their phone for the duration of the study

- Willing to give informed consent and comply with the investigational procedures

Exclusion Criteria:

- Currently or previously employed by SPD, Alere, Abbott, Unipath or P&G, or affiliates

- Has an immediate relative* currently or previously employed by SPD, Alere, Abbott, Unipath or P&G or affiliates

- There is a reason why the volunteer should not get pregnant e.g. they are taking a medication or have a medical condition which means they should not get pregnant

- Trying to conceive for more than 6 months (if less than 35 years old) and more than 3 months (if 35 years old or over)

- Has been diagnosed with Polycystic Ovarian Syndrome (PCOS)

- Has PCOS symptoms: very irregular cycles, hirsutism

- Using or has previously used infertility medications or hormone replacement therapy containing hCG or LH (e.g Pregnyl)

- Are taking clomiphene citrate or other ovulation induction drugs

- Using any treatment which may affect the menstrual cycle (e.g. the contraceptive pill)

- Currently pregnant or breastfeeding

- Peri- or post-menopausal, e.g. experiencing symptoms: Irregular menstrual periods, hot flushes, night sweats, sleep disturbances, and mood swings

- Have abnormal liver or kidney function

- Taking medication containing tetracycline

- Using or undergoing any other medical treatment for fertility such as ovulation drugs, artificial insemination and assisted fertility such as IVF or ICSI

- Has a phone that is known to be incompatible with COTS

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Clearblue Connected Ovulation Test System
Urinary LH test to predict ovulation

Locations

Country Name City State
United Kingdom SPD Development Company Ltd Bedford Bedfordshire

Sponsors (1)

Lead Sponsor Collaborator
SPD Development Company Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in pregnancy rates across 2 cycles of use between volunteers trying to conceive in the home setting using (i) COTS, (ii) no intervention. The difference in pregnancy rates between volunteers trying to conceive in the home setting using (i) COTS (ii) no intervention 2 months
Secondary Assessment of behaviour of women trying to conceive Quantitative assessment in methods used to try and help with conception and intercourse patterns. 2 months
Secondary Evaluation of women's experience of trying to conceive using COTS compared to not using ovulation tests Qualitative interview responses regarding usage and experience of COTS or other methods whilst trying to conceive. 2 months
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Completed NCT02528136 - The Clinical Carbetocin Myocardium Trial Phase 4